Shares keep falling even though Aspen spells out details of business
The company has lost more than a third of its value, or nearly R100 per share, since it released its results
Aspen Pharmacare’s shares slid another 8% on Wednesday even as the group issued a statement clarifying certain aspects of its business to stem a sell-off. This means the company has lost more than a third of its value, or nearly R100 per share, since it released results for the year ended June on September 13 and said it would sell its nutritionals business for less than the market expected. A voluntary clarification announcement on Wednesday failed to arrest the decline, with the share closing at R173.23, the lowest it has been in more than five years. That compares to a close of R272.50 a week before. Aspen said it expected organic revenue growth of 1%-4% in its commercial pharmaceuticals business for the 2019 financial year. To allay concerns from some investors, it said it had no off-balance sheet funding in place and that all guarantees to financial institutions only applied to wholly owned subsidiaries. Its guarantees to financial institutions were R73.5bn, while reported borr...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.